



21 April 2023

Our Ref: RFI 49278

Dear

**Freedom of Information Act 2000
Information in Relation to the usage of new Biologic and targeted
Medications within Dermatology**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 14 February 2023. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Manager (Interim)

Q1. Could you please tell me how many patients were treated in January 2023 (or latest available month) by the dermatology department with the following drugs:

A1. Please see Table 1.

Table 1

Treatment	No. of Patients Treated
Abrocitinib (Cibinqo)	Nil
Baricitinib (Olmiant)	Nil
Dupilumab (Dupixent)	32
Tralokinumab (Adtralza)	Nil
Upadacitinib (Rinvoq)	5